よむ、つかう、まなぶ。
【参考資料6】抗微生物薬適正使用の手引き 第三版 補遺 (42 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_45318.html |
| 出典情報 | 厚生科学審議会 感染症部会 薬剤耐性（AMR）に関する小委員会 抗微生物薬適正使用（AMS）等に関する作業部会（第6回 11／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
152. Hand E, Davis H, Kim T, Duhon B. Monotherapy with minocycline or
trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. J
Antimicrob Chemother. 2016 Apr;71(4):1071-1075.
153. Biagi M, Vialichka A, Jurkovic M. et al. Activity of Cefiderocol Alone and in Combination with
Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against
Multidrug-Resistant Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2020
Aug;64(9):e00559-20.
154. Morrissey I, Olesky M, Hawser S. et al. In Vitro Activity of Eravacycline against GramNegative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017. Antimicrob
Agents Chemother. 2020 Feb;64(3):e01699-19.
155. Sader HS, Duncan LR, Arends SJR, Carvalhaes CG, Castanheira M. Antimicrobial Activity of
Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of
Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide.
Antimicrob Agents Chemother. 2020 Oct;64(11):e01433-20.
156. Mojica MF, Papp-Wallace KM, Taracila MA. et al. Avibactam Restores the Susceptibility of
Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam. Antimicrob Agents
Chemother. 2017 Sep;61(10):e00777-17.
157. Mojica MF, Rutter JD, Taracila M. et al. Population Structure, Molecular Epidemiology, and
beta-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United
States. mBio. 2019 Jul;10(4):e00405-19.
158. Johnson S, Lavergne V, Skinner AM. et al. Clinical Practice Guideline by the Infectious
Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America
(SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection
in Adults. Clin Infect Dis. 2021 Sep;73(5):755-757.
159. Clostridioides difficile 感染症診療ガイドライン 公益社団法人日本化学療法学会・一般社団法
人日本感染症学会 CDI 診療ガイドライン作成委員会編. 2022. at
https://www.kansensho.or.jp/uploads/files/guidelines/guideline_cdi_230125.pdf.)
160. van Prehn J, Reigadas E, Vogelzang EH. et al. European Society of Clinical Microbiology
and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides
difficile infection in adults. Clin Microbiol Infect. 2021 Dec;27 Suppl 2:S1-S21.
161. Fitzpatrick F, Safdar N, van Prehn J, Tschudin-Sutter S. How can patients with Clostridioides
difficile infection on concomitant antibiotic treatment be best managed? Lancet Infect Dis.
2022 Nov;22(11):e336-e340.
162. Slimings C, Riley TV. Antibiotics and healthcare facility-associated Clostridioides difficile
infection: systematic review and meta-analysis 2020 update. J Antimicrob Chemother. 2021
Jun;76(7):1676-1688.
42
trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. J
Antimicrob Chemother. 2016 Apr;71(4):1071-1075.
153. Biagi M, Vialichka A, Jurkovic M. et al. Activity of Cefiderocol Alone and in Combination with
Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against
Multidrug-Resistant Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2020
Aug;64(9):e00559-20.
154. Morrissey I, Olesky M, Hawser S. et al. In Vitro Activity of Eravacycline against GramNegative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017. Antimicrob
Agents Chemother. 2020 Feb;64(3):e01699-19.
155. Sader HS, Duncan LR, Arends SJR, Carvalhaes CG, Castanheira M. Antimicrobial Activity of
Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of
Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide.
Antimicrob Agents Chemother. 2020 Oct;64(11):e01433-20.
156. Mojica MF, Papp-Wallace KM, Taracila MA. et al. Avibactam Restores the Susceptibility of
Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam. Antimicrob Agents
Chemother. 2017 Sep;61(10):e00777-17.
157. Mojica MF, Rutter JD, Taracila M. et al. Population Structure, Molecular Epidemiology, and
beta-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United
States. mBio. 2019 Jul;10(4):e00405-19.
158. Johnson S, Lavergne V, Skinner AM. et al. Clinical Practice Guideline by the Infectious
Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America
(SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection
in Adults. Clin Infect Dis. 2021 Sep;73(5):755-757.
159. Clostridioides difficile 感染症診療ガイドライン 公益社団法人日本化学療法学会・一般社団法
人日本感染症学会 CDI 診療ガイドライン作成委員会編. 2022. at
https://www.kansensho.or.jp/uploads/files/guidelines/guideline_cdi_230125.pdf.)
160. van Prehn J, Reigadas E, Vogelzang EH. et al. European Society of Clinical Microbiology
and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides
difficile infection in adults. Clin Microbiol Infect. 2021 Dec;27 Suppl 2:S1-S21.
161. Fitzpatrick F, Safdar N, van Prehn J, Tschudin-Sutter S. How can patients with Clostridioides
difficile infection on concomitant antibiotic treatment be best managed? Lancet Infect Dis.
2022 Nov;22(11):e336-e340.
162. Slimings C, Riley TV. Antibiotics and healthcare facility-associated Clostridioides difficile
infection: systematic review and meta-analysis 2020 update. J Antimicrob Chemother. 2021
Jun;76(7):1676-1688.
42